The global pediatric cancer biomarkers market size is anticipated to reach USD 1.45 billion by 2030 and is projected to grow at a CAGR 8.5% from 2024 to 2030. The rise in the number of pediatric cancer cases globally is a major driver for market expansion. According to a February 2023 NIH report, approximately 400,000 children and adolescents aged 0-19 are diagnosed with cancer globally each year. Pediatric cancers are distinct from those in adults, with the most prevalent types being leukemias, followed by central nervous system (CNS) tumors and lymphomas. According to various health organizations, pediatric cancers, while rarer than adult cancers, are increasingly being diagnosed due to better diagnostic technologies and heightened awareness.
Significant research efforts are uncovering novel biomarkers that can enhance early detection and treatment of pediatric cancers. For instance, in June 2024, researchers at the Children’s Hospital of Philadelphia (CHOP) announced the discovery of a new immune-based biomarker. This promising biomarker could revolutionize early detection methods, potentially identifying ovarian cancer two to four years before it typically manifests. Such breakthroughs are crucial for improving pediatric oncology treatment outcomes and survival rates. As research continues to yield innovative biomarkers, the market is expanding, with increased investments and focus on developing advanced diagnostic tools. This progress not only supports earlier and more accurate diagnosis but also drives the overall growth of the pediatric cancer biomarkers market.
Additionally, collaboration between academic institutions, research organizations, and pharmaceutical companies drives innovation in the pediatric cancer biomarkers market. Joint research efforts and partnerships facilitate developing and validating new biomarkers through shared expertise and resources. Collaborative initiatives, such as multi-center For instance, in February 2022, Lantern Pharma announced its expansion into additional pediatric cancers through a partnership with The Greehey Children Cancer Research Institute at the University of Texas Health Science Center. studies and public-private partnerships, accelerate the discovery and commercialization of advanced biomarkers. These partnerships enhance the efficiency of research and development processes, contributing to market growth by bringing novel biomarkers to market more rapidly and effectively.
Furthermore, the expansion and improvement of healthcare infrastructure, particularly in emerging markets, are facilitating the growth of the pediatric cancer biomarkers market. As healthcare systems in various regions develop and modernize, there is greater access to advanced diagnostic technologies and biomarker tests. Improved healthcare facilities and services enable the broader implementation of pediatric cancer biomarkers, enhancing diagnostic accuracy and treatment efficacy.
This product will be delivered within 1-3 business days.
Significant research efforts are uncovering novel biomarkers that can enhance early detection and treatment of pediatric cancers. For instance, in June 2024, researchers at the Children’s Hospital of Philadelphia (CHOP) announced the discovery of a new immune-based biomarker. This promising biomarker could revolutionize early detection methods, potentially identifying ovarian cancer two to four years before it typically manifests. Such breakthroughs are crucial for improving pediatric oncology treatment outcomes and survival rates. As research continues to yield innovative biomarkers, the market is expanding, with increased investments and focus on developing advanced diagnostic tools. This progress not only supports earlier and more accurate diagnosis but also drives the overall growth of the pediatric cancer biomarkers market.
Additionally, collaboration between academic institutions, research organizations, and pharmaceutical companies drives innovation in the pediatric cancer biomarkers market. Joint research efforts and partnerships facilitate developing and validating new biomarkers through shared expertise and resources. Collaborative initiatives, such as multi-center For instance, in February 2022, Lantern Pharma announced its expansion into additional pediatric cancers through a partnership with The Greehey Children Cancer Research Institute at the University of Texas Health Science Center. studies and public-private partnerships, accelerate the discovery and commercialization of advanced biomarkers. These partnerships enhance the efficiency of research and development processes, contributing to market growth by bringing novel biomarkers to market more rapidly and effectively.
Furthermore, the expansion and improvement of healthcare infrastructure, particularly in emerging markets, are facilitating the growth of the pediatric cancer biomarkers market. As healthcare systems in various regions develop and modernize, there is greater access to advanced diagnostic technologies and biomarker tests. Improved healthcare facilities and services enable the broader implementation of pediatric cancer biomarkers, enhancing diagnostic accuracy and treatment efficacy.
Pediatric Cancer Biomarkers Market Report Highlights
- Based on indication, the leukemia segment held the largest share of 40.8% in 2023, owing to the high incidence and need for early detection of this cancer type.
- Based on biomarker, the CD19, CD20, and CD22 segments held the largest share of 29.7% in 2023, due to their critical roles in diagnosing and targeting hematological cancers. Advances in targeted therapies, such as CAR-T cell therapies, utilize these biomarkers to improve treatment efficacy and patient outcomes. Their growing application in precision medicine is significantly contributing to market expansion.
- In terms of end use, the hospital segment held the largest share of 40.5% in 2023, driven by increasing investments and government support. Hospitals are adopting advanced biomarker technologies to improve diagnostic accuracy and personalized treatments for pediatric cancers. Government initiatives, such as funding for research and development and incentives for implementing innovative diagnostics, are bolstering market expansion.
- North America pediatric cancer biomarkers market dominated the overall global market and accounted for the 43.8% revenue share in 2023due to advanced research, increasing cancer incidence, and significant investments in healthcare infrastructure. Enhanced diagnostic technologies and a focus on personalized medicine are driving market expansion, alongside substantial funding and supportive government policies for pediatric cancer research and treatment.
The leading players in the Pediatric Cancer Biomarkers market include:
- F. Hoffmann-La Roche Ltd
- Abbott
- Siemens Healthineers
- Thermo Fisher Scientific
- QIAGEN
- Myriad Genetics
- Beckman Coulter
- Bio-Rad Laboratories
- Agilent Technologies
- BIOMÉRIEUX
- RayBiotech, Inc
- Randox Laboratories Ltd.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pediatric Cancer Biomarkers Market Variables, Trends & Scope
Chapter 4. Pediatric Cancer Biomarkers Market: Indication Estimates & Trend Analysis
Chapter 5. Pediatric Cancer Biomarkers Market: Biomarker Estimates & Trend Analysis
Chapter 6. Pediatric Cancer Biomarkers Market: End Use Estimates & Trend Analysis
Chapter 7. Pediatric Cancer Biomarkers Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- F. Hoffmann-La Roche Ltd
- Abbott
- Siemens Healthineers
- Thermo Fisher Scientific
- QIAGEN
- Myriad Genetics
- Beckman Coulter
- Bio-Rad Laboratories
- Agilent Technologies
- BIOMÉRIEUX
- RayBiotech, Inc
- Randox Laboratories Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 815.81 Million |
| Forecasted Market Value ( USD | $ 1450 Million |
| Compound Annual Growth Rate | 8.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
